SCHEMBL1128575

SCHEMBL1128575

CC(C)c1noc(N2CCC(n3ncc4c(Oc5ccc(S(C)(=O)=O)cc5F)ncnc43)CC2)n1

nearest known ligand 0.56

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 17/20 0.56
CYP3A4 P08684 4/20 0.55
CYP2C19 P33261 1/20 0.55
KCNH2 Q12809 2/20 0.47
CYP2C9 P11712 3/20 0.46
GPR183 P32249 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1128483 0.88 CYP3A4 (0.60) GPR119CYP3A4CYP2C19KCNH2GPR183
SCHEMBL1128505 0.88 GPR119 (0.52) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL1128552 0.88 GPR119 (0.52) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL4355567 0.88 GPR119 (0.52) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL10139809 0.87 GPR119 (0.56) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL1128738 0.86 CYP3A4 (0.48) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL12574301 0.82 CYP3A4 (0.51) GPR119CYP3A4KCNH2CYP2C9
SCHEMBL388432 0.82 GPR119 (0.69) GPR119CYP3A4CYP2C19KCNH2CYP2C9
SCHEMBL2026661 0.82 GPR119 (0.58) GPR119CYP3A4CYP2C9
SCHEMBL2020760 0.81 CYP3A4 (0.52) GPR119CYP3A4KCNH2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US claimed
EP-2283019-A1 GPR119 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2011-02-16 EP claimed
WO-2009141238-A1 GPR119 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-26 WO claimed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US claimed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
US-8188098-B2 GPR119 receptor agonists HOFFMANN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2283019-A1 GPR119 RECEPTOR AGONISTS F. Hoffmann-La Roche AG (CH) 2011-02-16 EP disclosed
WO-2009141238-A1 GPR119 RECEPTOR AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2009-11-26 WO disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed
US-20090286812-A1 GPR119 Receptor Agonists ERICKSON SHAWN DAVID 2009-11-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090286812-A1 GPR119 Receptor Agonists GPR119, GPR27, GPR139 GPR119 1/4885CYP3A4 1503/4885CYP2C19 621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.